RxDoctor Payments DataLook up a doctor →

Cynthia Lynch, MD

Hematology & Oncology · Goodyear, AZNPI 1790726255

Payments from drug & device makers

$3,799,679in general payments, 2019–2025

Across 334 payments — averaging $11,376 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.2M
  • Merck$854K
  • Seagen Inc.$735K
  • Boehringer Ingelheim$638K
  • Daiichi Sankyo Inc.$192K
  • Macrogenics, Inc.$89K
  • plus $112K from 10 others

What the payments were for

  • Consulting fees$4,87074%
  • Speaking & faculty fees$1,45022%
  • Food & beverage$2704%
  • Education$120%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,799,679 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$46,879
Medicare patients
234
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrserduElacestrant Hcl19$433,794
IbrancePalbociclib23$355,298
Letrozole168$4,560
Tamoxifen Citrate60$1,732
Exemestane15$1,482
Anastrozole50$855
Dexamethasone16$484
Prochlorperazine Maleate20$206
Ondansetron Hcl24$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$35,260$355,29823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 261 hematology & oncology providers in Arizona.

Other hematology & oncology in Goodyear

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →